Condition: Metastatic Colorectal Cancer · Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
NIPIRESCUE evaluates nivolumab and ipilimumab in patients with MSI/dMMR mCRC resistant to anti-PD1 monotherapy and previously treated with fluoropyrimidine, oxaliplatine, irinotecan, and anti- vascular endothelial growth factor (VEGF) or anti- epidermal growth factor receptor (EGFR) therapy.
This description comes directly from the study's public registry record.
Marie Line GARCIA LARNICOL, MD · 01 40 29 85 00 · marie-line.garcia-larnicol@gercor.com.fr
Always discuss trial participation with your own doctor first.
| CHU Jean Minjoz | Besançon, France | Recruiting |
| Institute Bergonie | Bordeaux, France | Recruiting |
| CHRU Lille | Lille, France | Recruiting |
| CHU Dupuytren | Limoges, France | Recruiting |
| Centre Léon Bérard | Lyon, France | Recruiting |
| ICM Val d'Aurelle | Montpellier, France | Recruiting |
| Centre Antoine Lacassagne | Nice, France | Recruiting |
| Hôpital Saint Antoine | Paris, France | Recruiting |
| CHU Poitiers | Poitiers, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05310643